Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer.
Cells
; 9(11)2020 11 17.
Article
em En
| MEDLINE
| ID: mdl-33212909
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Receptores Androgênicos
/
Biomarcadores Tumorais
/
Neoplasias de Próstata Resistentes à Castração
/
Metástase Neoplásica
Tipo de estudo:
Diagnostic_studies
/
Guideline
/
Prognostic_studies
Limite:
Humans
/
Male
Idioma:
En
Revista:
Cells
Ano de publicação:
2020
Tipo de documento:
Article